Structure Therapeutics
GPCR
164 hedge funds and large institutions have $1.65B invested in Structure Therapeutics in 2024 Q4 according to their latest regulatory filings, with 29 funds opening new positions, 65 increasing their positions, 49 reducing their positions, and 23 closing their positions.
63% more call options, than puts
Call options by funds: $28.1M | Put options by funds: $17.3M
33% more repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 49
26% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 23
3% more funds holding
Funds holding: 160 → 164 (+4)
0.49% less ownership
Funds ownership: 35.81% → 35.31% (-0.49%)
29% less funds holding in top 10
Funds holding in top 10: 7 → 5 (-2)
39% less capital invested
Capital invested by funds: $2.69B → $1.65B (-$1.04B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$56M |
| 2 |
VPC
Vestal Point Capital
New York
|
+$20.4M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$16M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
+$11.4M |
| 5 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$10.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OCA
Octagon Capital Advisors
New York
|
-$52.6M |
| 2 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$31.4M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$27M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$24.5M |
| 5 |
LGM
Logos Global Management
San Francisco,
California
|
-$19.5M |
GPCR Hedge Fund Activity: Q4 2024 in Review
164 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Structure Therapeutics (GPCR) for Q4 2024, worth a combined $1.65B — down 39% from $2.69B a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new GPCR positions and 23 closed out — a net gain of 6 holders — while 65 added to existing stakes and 49 trimmed.
The largest buyer was Deep Track Capital, adding an estimated $56M. The largest seller was Octagon Capital Advisors, exiting entirely with an estimated $52.6M sold.
- 164 institutional investors held Structure Therapeutics (GPCR) as of Q4 2024, up from 160 in Q3 2024.
- Funds reported $1.65B of Structure Therapeutics stock for Q4 2024, down 39% quarter-over-quarter.
- 29 funds opened new Structure Therapeutics positions in Q4 2024 and 23 closed out, a net change of +6 holders.
- The largest Structure Therapeutics buyer in Q4 2024 was Deep Track Capital, an estimated $56M added.
- The largest Structure Therapeutics seller in Q4 2024 was Octagon Capital Advisors, an estimated $52.6M sold.
Based on aggregated 13F filings for Q4 2024.